Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

Completed

• Conditions: Carbapenem Resistant Bacterial Infection; Bacteremia; Proteus Mirabilis Infection
• Interventions: Other: Non-Interventional Research

• Registration Number: NCT06542965
• Lead Sponsor: Dokuz Eylul University

Brief Summary

This study aims to determine the clinical characteristics, risk factors, and resistance mechanisms of patients with carbapenem-resistant P. mirabilis bacteremia.Patients with P. mirabilis growth in blood culture samples sent to bacteriology laboratory between 2018 and 2021 were retrospectively analyzed. Patients meeting the inclusion criteria were divided into carbapenem-resistant and carbapenem- susceptible groups. The investigators recorded demographic data, clinical features, and laboratory findings. Resistance genes were investigated in carbapenem-resistant isolates using PCR.

Detailed Description

Patients with P. mirabilis growth in blood culture who met the study criteria were divided into two groups as carbapenem susceptible and resistant according to carbapenem antibiogram results. Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group and patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group.

Demographic characteristics of the patients, concomitant chronic diseases, Charlson comorbidity index (CCI), hospital and intensive care unit (ICU) hospitalization and number of days in the last year, history and type of invasive intervention in the last three months (surgical-invasive), history of antibiotic use in the last three months and types of antibiotics used (Penicillin, cephalosporin, quinolone, carbapenem, tigecycline, colistin, aminoglycoside), hospitalization unit, total length of hospitalization, sample collection unit, growth result and antibiogram, clinical and laboratory data of the day of growth, sepsis and septic shock evaluated according to systemic inflammatory response syndrome (SIRS) criteria, 30-day mortality and patient outcome information were recorded.

Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction (PCR) in accessible samples of patients with carbapenem-resistant P. mirabilis growth in blood cultures.

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2021-12-31
• Study Completion: 2023-01-01
• Study First Submitted: 2024-07-31
• Status Verified: 2024-08
• Study First Submitted QC: 2024-08-03
• Last Update Submitted: 2024-08-03
• Study First Posted: 2024-08-07
• Last Update Posted: 2024-08-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 67

Inclusion Criteria

• Inpatients aged 18 years and older
• P. mirabilis growth in blood cultures

Exclusion Criteria

• Samples taken in emergency departments, outpatient clinics, day treatment units
• Recurrent growths of the same patient

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Case (Patients with carbapenem-resistant P. mirabilis)	Non-Interventional Research	Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group
Control (Patients with carbapenem- susceptible P. mirabilis)	Non-Interventional Research	Patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group

Primary Outcome Measures

Name	Time	Method
Carbapenem Use	1 year	number of patients using carbapenem before P. mirabilis growth in blood cultures
Presence of chronic disease	1 year	number of patients with chronic disease
Intensive Care Units	1 year	number of patients admission in ıntensive care units before P. mirabilis growth in blood cultures
Length of hospital stay	1 year	Length of hospital stay days
Mortality	30 days	number of patients who died

Trial Locations

Locations (1)

Dokuz Eylül University; 🇹🇷 İzmir, Turkey